Latest filings (excl ownership)
15-12G
Securities registration termination
25 Sep 19
SC 13E3/A
Going private transaction (amended)
9 Sep 19
8-K
Entry into a Material Definitive Agreement
26 Aug 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
DEF 14A
Definitive proxy
10 Jul 19
SC 13E3/A
Going private transaction (amended)
3 Jul 19
PRER14A
Preliminary revised proxy
3 Jul 19
CORRESP
Correspondence with SEC
3 Jul 19
UPLOAD
Letter from SEC
28 Jun 19
SC 13E3
Going private transaction
31 May 19
PRE 14A
Preliminary proxy
31 May 19
10-Q
2019 Q1
Quarterly report
13 May 19
10-K
2018 FY
Annual report
22 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 19
8-K
Entry into a Material Definitive Agreement
19 Mar 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
10-Q
2018 Q2
Quarterly report
13 Aug 18
10-Q
2018 Q1
Quarterly report
11 May 18
8-K
LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China
7 May 18
10-K
2017 FY
Annual report
28 Feb 18
8-K
Entry into a Material Definitive Agreement
1 Feb 18
10-Q
2017 Q3
Quarterly report
13 Nov 17
10-K/A
2016 FY
Annual report (amended)
30 Oct 17
10-Q
2017 Q2
Quarterly report
14 Aug 17
8-K
Changes in Registrant's Certifying Accountant
14 Aug 17
8-K
Capstone Therapeutics Announces Transaction for Sale of Shares of Its Common Stock and Secured Loan
17 Jul 17
D
$3.44M in equity / debt
17 Jul 17
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
30 Jun 17
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
15 Jun 17
10-Q
2017 Q1
Quarterly report
4 May 17
8-A12G
Registration of securities
19 Apr 17
8-K
Entry into a Material Definitive Agreement
19 Apr 17
10-K
2016 FY
Annual report
15 Mar 17
10-Q
2016 Q3
Quarterly report
10 Nov 16
8-K
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
26 Aug 16
10-Q
2016 Q2
Quarterly report
29 Jul 16
10-Q
2016 Q1
Quarterly report
13 May 16
Latest ownership filings
SC 13D/A
Capstone Therapeutics Corp.
20 Aug 19
SC 13D/A
Capstone Therapeutics Corp.
19 Mar 19
SC 13G/A
Capstone Therapeutics Corp.
13 Feb 19
SC 13G
Capstone Therapeutics Corp.
11 Feb 19
3
Initial statement of insider ownership
4 Feb 19
4
NEIL S SUBIN
28 Dec 18
SC 13D/A
Capstone Therapeutics Corp.
20 Nov 18
SC 13D/A
Capstone Therapeutics Corp.
18 May 18
4
Matthew E. Lipman
1 Feb 18
SC 13D/A
Capstone Therapeutics Corp.
1 Feb 18
SC 13G
Capstone Therapeutics Corp.
23 Jan 18
3
NEIL S SUBIN
22 Jan 18
4
LLOYD I MILLER III
10 Oct 17
3
MICHAEL TOPOREK
24 Jul 17
3
Matthew E. Lipman
24 Jul 17
SC 13D
Capstone Therapeutics Corp.
24 Jul 17
4
MARK N LAMPERT
18 Jul 17
SC 13G/A
Capstone Therapeutics Corp.
18 Jul 17
SC 13G/A
Capstone Therapeutics Corp.
26 Jan 17
4
LESLIE M TAEGER
6 Jan 17
4
LLOYD I MILLER III
19 Dec 16
4
LLOYD I MILLER III
16 Dec 16
4
ELWOOD D HOWSE
14 Nov 16
4
FREDRIC J FELDMAN
14 Nov 16
4
LLOYD I MILLER III
15 Aug 16
4
LLOYD I MILLER III
2 Aug 16
4
LLOYD I MILLER III
9 Jun 16
SC 13G
Capstone Therapeutics Corp.
24 Mar 16
SC 13G/A
Capstone Therapeutics Corp.
16 Feb 16
4
FREDRIC J FELDMAN
25 Jan 16
4
ELWOOD D HOWSE
25 Jan 16
4
Eric W Fangmann
25 Jan 16
4
JOHN M HOLLIMAN III
25 Jan 16
4
JOHN M HOLLIMAN III
21 Dec 15
4
RANDOLPH C STEER
23 Jun 15
4
Eric W Fangmann
23 Jun 15
4
LESLIE M TAEGER
23 Jun 15
4
ELWOOD D HOWSE
23 Jun 15
4
JOHN M HOLLIMAN III
23 Jun 15
4
FREDRIC J FELDMAN
23 Jun 15